menu
    • menu

    Company profile for Merck Group

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in Darmstadt, Germany in 1668 by Friedrich Jacob Merck, Merck KGaA is the world’s oldest pharmaceutical and chemical company. Merck is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. They are known as Merck internationally. In the United States and Canada, however, they operate as EMD Serono in the Biopharma business, as MilliporeSigma in the ...
    Founded in Darmstadt, Germany in 1668 by Friedrich Jacob Merck, Merck KGaA is the world’s oldest pharmaceutical and chemical company. Merck is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. They are known as Merck internationally. In the United States and Canada, however, they operate as EMD Serono in the Biopharma business, as MilliporeSigma in the Life Science business, and as EMD Performance Materials in the materials business.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Merck GroupGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Frankfurter Strasse 250, 64293 Darmstadt
    Telephone
    Telephone
    +49 (0) 6151 72-0
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.merckgroup.com/de
    Linkedin
    Linkedin
    https://in.linkedin.com/company/merck-group
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/merckgroup?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EMD Serono Innovates Rare Neuromuscular Disorder Treatment
    EMD Serono Innovates Rare Neuromuscular Disorder Treatment

    24 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251124788420/en/EMD-Serono-Takes-Patient-Directed-Approach-to-Bring-Innovation-to-the-Treatment-of-Rare-Neuromuscular-Disorder-Generalized-Myasthenia-Gravis

    BUSINESSWIRE
    24 Nov 2025
    Share Share
    Merck KGAa Deploys Supercomputer For Scientific Advancements
    Merck KGAa Deploys Supercomputer For Scientific Advancements

    21 Nov 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/rd/merck-kgaa-fires-up-new-supercomputer-to-turbocharge-scientific-breakthroughs-18294

    INDPHARMAPOST
    21 Nov 2025
    Share Share
    Merck KGaA Becomes Latest Partner For Flagship's Valo Health
    Merck KGaA Becomes Latest Partner For Flagship's Valo Health

    20 Nov 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/3b-deal-merck-kgaa-becomes-latest-big-pharma-partner-drug-discoverer-valo-health

    FIERCE BIOTECH
    20 Nov 2025
    Share Share
    Merck KGaA Maintains Flat Q3 2025 Net Sales Amid Uncertainty
    Merck KGaA Maintains Flat Q3 2025 Net Sales Amid Uncertainty

    14 Nov 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/merck-kgaa-q3-2025-net-sales-remains-flat-amid-geopolitical-uncertainty-18231

    INDPHARMAPOST
    14 Nov 2025
    Share Share
    Merck Life Science Hosts ‘SPARK’ Science Engagement
    Merck Life Science Hosts ‘SPARK’ Science Engagement

    05 Nov 2025

    // EXPRESSPHARMA

    https://www.expresspharma.in/merck-life-science-hosts-spark-science-engagement-for-school-students-in-bengaluru/

    EXPRESSPHARMA
    05 Nov 2025
    Share Share
    Merck Collab With Promega To Enhance 3D Cell Drug Technology
    Merck Collab With Promega To Enhance 3D Cell Drug Technology

    28 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251028493228/en/Merck-Partners-with-Promega-to-Advance-3-D-Cell-Drug-Discovery-Technologies

    BUSINESSWIRE
    28 Oct 2025
    Share Share

    CEP/COS

    read-more
    read-more

    01

    Bisoprolol fumarate

    CEP/COS

    BIO Partnering at JPM
    Not Confirmed
    arrow

    02

    Boric Acid

    CEP/COS

    BIO Partnering at JPM
    Not Confirmed
    arrow

    03

    Dipotassium phosphate

    CEP/COS

    BIO Partnering at JPM
    Not Confirmed
    arrow

    04

    Magnesium chloride hexahydrate

    CEP/COS

    BIO Partnering at JPM
    Not Confirmed
    arrow

    05

    Meglumine

    CEP/COS

    BIO Partnering at JPM
    Not Confirmed
    arrow

    06

    Potassium iodide

    CEP/COS

    BIO Partnering at JPM
    Not Confirmed
    arrow

    07

    Praziquantel

    CEP/COS

    BIO Partnering at JPM
    Not Confirmed
    arrow

    08

    Sodium fluoride

    CEP/COS

    BIO Partnering at JPM
    Not Confirmed
    arrow

    09

    Urea

    CEP/COS

    BIO Partnering at JPM
    Not Confirmed
    arrow

    10

    Zinc chloride

    CEP/COS

    BIO Partnering at JPM
    Not Confirmed
    arrow
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    JDMF

    read-more
    read-more

    01

    Calcium chloride hydrate

    JDMF

    BIO Partnering at JPM
    Not Confirmed
    arrow

    Calcium chloride hydrate

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Merck Group

    Registration Number : 307MF10109

    Registrant's Address : Frankfurter Strasse 250 64293 Darmstadt Germany

    Initial Date of Registration : 2025-08-28

    Latest Date of Registration : 2025-08-28

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Saffinamide mesylate

    JDMF

    BIO Partnering at JPM
    Not Confirmed
    arrow

    Saffinamide mesylate

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Merck Group

    Registration Number : 230MF10101

    Registrant's Address : Frankfurter Strasse 250 64293 Darmstadt Germany

    Initial Date of Registration : 2018-08-02

    Latest Date of Registration : 2018-08-02

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Culture medium/culture medium additives:...

    JDMF

    BIO Partnering at JPM
    Not Confirmed
    arrow

    Culture medium/culture medium additives:...

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Merck Group

    Registration Number : 307MF40051

    Registrant's Address : Frankfurter Strasse 250 64293 Darmstadt Germany

    Initial Date of Registration : 2025-09-26

    Latest Date of Registration : 2025-09-26

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KDMF

    read-more
    read-more

    01

    Safinamide mesylate

    Germany
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Safinamide mesylate

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck Group

    Registrant Name : Korea Ezai Co., Ltd.

    Registration Date : 2020-06-24

    Registration Number : Su140-6-ND

    Manufacturer Name : Merck KGaA

    Manufacturer Address : Frankfurter Straße 250 D-64293 Darmstadt, Germany

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    Details:

    M7437 is a antibody-drug conjugate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.


    Lead Product(s): M7437

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Antibody-drug Conjugate

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 31, 2025

    blank

    01

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : M7437

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    Details : M7437 is a antibody-drug conjugate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

    Product Name : Undisclosed

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    December 31, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Abbisko's Pimicotinib Approved by China NMPA for Tenosynovial Giant Cell Tumor

    Details:

    Pimicotinib, a CSF1R inhibitor, shows promise in treating Tenosynovial Giant Cell Tumor (TGCT).


    Lead Product(s): Pimicotinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Recipient: Abbisko Therapeutics

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 22, 2025

    blank

    02

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pimicotinib

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Recipient : Abbisko Therapeutics

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Abbisko's Pimicotinib Approved by China NMPA for Tenosynovial Giant Cell Tumor

    Details : Pimicotinib, a CSF1R inhibitor, shows promise in treating Tenosynovial Giant Cell Tumor (TGCT).

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    December 22, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin

    Details:

    Desogestrel is a Hormone drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Fertility.


    Lead Product(s): Desogestrel,Ethinyl Estradiol,Follitropin Alfa,Lutropin Alfa

    Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Hormone

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 08, 2025

    blank

    03

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Desogestrel,Ethinyl Estradiol,Follitropin Alfa,Lutropin Alfa

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasi...

    Details : Desogestrel is a Hormone drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Fertility.

    Product Name : Undisclosed

    Product Type : Hormone

    Upfront Cash : Inapplicable

    December 08, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Valo Health Collaborates with Merck KGaA to Develop Treatments for Parkinson’s Disease

    Details:

    The collaboration aims to develop a new treatment for Parkinson's disease.


    Lead Product(s): Undisclosed

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Discovery PlatformProduct Type: Miscellaneous

    Recipient: Valo Health

    Deal Size: $3,000.0 million Upfront Cash: Undisclosed

    Deal Type: Collaboration November 20, 2025

    blank

    04

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Neurology

    Highest Development Status : Discovery Platform

    Recipient : Valo Health

    Deal Size : $3,000.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Valo Health Collaborates with Merck KGaA to Develop Treatments for Parkinson’s Disease

    Details : The collaboration aims to develop a new treatment for Parkinson's disease.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    November 20, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive

    Details:

    Evobrutinib is a Miscellaneous drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Contraception.


    Lead Product(s): Evobrutinib,Ethinyl Estradiol,Norethisterone

    Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 14, 2025

    blank

    05

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Evobrutinib,Ethinyl Estradiol,Norethisterone

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive

    Details : Evobrutinib is a Miscellaneous drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Contraception.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    October 14, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Relative Bioavailability of Evobrutinib Tablet Batches

    Details:

    Evobrutinib is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.


    Lead Product(s): Evobrutinib

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 09, 2025

    blank

    06

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Evobrutinib

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Relative Bioavailability of Evobrutinib Tablet Batches

    Details : Evobrutinib is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    October 09, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A TQT Study of Effect of M2951 on Cardiac Repolarization

    Details:

    Evobrutinib is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.


    Lead Product(s): Evobrutinib,Moxifloxacin

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 09, 2025

    blank

    07

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Evobrutinib,Moxifloxacin

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A TQT Study of Effect of M2951 on Cardiac Repolarization

    Details : Evobrutinib is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    October 09, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

    Details:

    M0324 is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.


    Lead Product(s): M0324,Pembrolizumab,Oxaliplatin

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Antibody, Unconjugated

    Recipient: EMD Serono

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 10, 2025

    blank

    08

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : M0324,Pembrolizumab,Oxaliplatin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Recipient : EMD Serono

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Se...

    Details : M0324 is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    September 10, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck KGaa Swoops to $2b Neurological Disease Pact with Skyhawk

    Details:

    The collaboration will focus on the discovery of novel RNA-targeting small molecules in select neurological indications with high unmet medical need.


    Lead Product(s): Undisclosed

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Discovery PlatformProduct Type: Miscellaneous

    Recipient: Skyhawk Therapeutics

    Deal Size: $2,000.0 million Upfront Cash: Undisclosed

    Deal Type: Collaboration August 18, 2025

    blank

    09

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Neurology

    Highest Development Status : Discovery Platform

    Recipient : Skyhawk Therapeutics

    Deal Size : $2,000.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Merck KGaa Swoops to $2b Neurological Disease Pact with Skyhawk

    Details : The collaboration will focus on the discovery of novel RNA-targeting small molecules in select neurological indications with high unmet medical need.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    August 18, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Anti-EGFR Therapy in Right-sided Advanced Colorectal Cancer with WT RAS & High AREG/EREG

    Details:

    Cetuximab is a Antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Colorectal Neoplasms.


    Lead Product(s): Cetuximab,Irinotecan Hydrochloride,Oxaliplatin,Calcium Folinate,Fluorouracil

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Antibody, Unconjugated

    Recipient: Gruppo Oncologico del Nord-Ovest

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 31, 2025

    blank

    10

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Merck Group

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cetuximab,Irinotecan Hydrochloride,Oxaliplatin,Calcium Folinate,Fluorouracil

    Therapeutic Area : Oncology

    Highest Development Status : Phase IV

    Recipient : Gruppo Oncologico del Nord-Ovest

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Anti-EGFR Therapy in Right-sided Advanced Colorectal Cancer with WT RAS & High AREG/EREG

    Details : Cetuximab is a Antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Colorectal Neoplasms.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    July 31, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Brand Name : Bavencio

    Germany
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : Bavencio

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Allowed

    Registration Country : Switzerland

    Avelumab

    Merck Group

    Dosage Form : Concentrate For Solution...

    Brand Name : Bavencio

    Dosage Strength : 200mg/10ml

    Packaging :

    Approval Date : 05/09/2017

    Application Number : 66380

    Regulatory Info : Allowed

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : Saizen Liquid (ml)

    Germany
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : Saizen Liquid (ml)

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Allowed

    Registration Country : Switzerland

    Somatropin (rDNA)

    Merck Group

    Dosage Form : Solution For Injection

    Brand Name : Saizen Liquid (ml)

    Dosage Strength : 6mg/5.83mg

    Packaging :

    Approval Date : 17/12/2010

    Application Number : 60570

    Regulatory Info : Allowed

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : Saizen Liquid (ml)

    Germany
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : Saizen Liquid (ml)

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Allowed

    Registration Country : Switzerland

    Somatropin (rDNA)

    Merck Group

    Dosage Form : Solution For Injection

    Brand Name : Saizen Liquid (ml)

    Dosage Strength : 12mg/8mg

    Packaging :

    Approval Date : 17/12/2010

    Application Number : 60570

    Regulatory Info : Allowed

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : Saizen Liquid (ml)

    Germany
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : Saizen Liquid (ml)

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Allowed

    Registration Country : Switzerland

    Somatropin (rDNA)

    Merck Group

    Dosage Form : Solution For Injection

    Brand Name : Saizen Liquid (ml)

    Dosage Strength : 20mg/8mg

    Packaging :

    Approval Date : 17/12/2010

    Application Number : 60570

    Regulatory Info : Allowed

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : Campral

    Germany
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : Campral

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Allowed

    Registration Country : Switzerland

    Acamprosate

    Merck Group

    Dosage Form : Film Coated Tablet

    Brand Name : Campral

    Dosage Strength : 300mg

    Packaging :

    Approval Date : 1995-08-29

    Application Number : 53090

    Regulatory Info : Allowed

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : Besobrial

    Germany
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : Besobrial

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    Acamprosate Calcium

    Merck Group

    Dosage Form : TAB

    Brand Name : Besobrial

    Dosage Strength : 333mg

    Packaging : 180X1mg

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : Emcor 5/5 FDC

    Germany
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : Emcor 5/5 FDC

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    Amlodipine

    Merck Group

    Dosage Form : TAB

    Brand Name : Emcor 5/5 FDC

    Dosage Strength : 5mg

    Packaging : 30X1mg

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : Emcor 5/10 FDC

    Germany
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : Emcor 5/10 FDC

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    Amlodipine

    Merck Group

    Dosage Form : TAB

    Brand Name : Emcor 5/10 FDC

    Dosage Strength : 10mg

    Packaging : 30X1mg

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : Emcor 10/5 FDC

    Germany
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : Emcor 10/5 FDC

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    Amlodipine

    Merck Group

    Dosage Form : TAB

    Brand Name : Emcor 10/5 FDC

    Dosage Strength : 5mg

    Packaging : 30X1mg

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : Emcor 10/10 FDC

    Germany
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : Emcor 10/10 FDC

    Germany
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    Amlodipine

    Merck Group

    Dosage Form : TAB

    Brand Name : Emcor 10/10 FDC

    Dosage Strength : 10mg

    Packaging : 30X1mg

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Services

    Upload your portfolio for free, ask us

    Drug Product Manufacturing

    Click here to discover the service providers for Drug Product Manufacturing

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Merck KGaA and get a quotation

    Merck KGaA is a supplier offers 16 products (APIs, Excipients or Intermediates).

    Find a price of Bisoprolol Fumarate bulk with DMF, CEP offered by Merck KGaA

    Find a price of Boric Acid bulk with DMF, CEP offered by Merck KGaA

    Find a price of Magnesium Chloride bulk with DMF, CEP offered by Merck KGaA

    Find a price of Meglumine bulk with DMF, CEP offered by Merck KGaA

    Find a price of Potassium Iodide bulk with DMF, CEP offered by Merck KGaA

    Find a price of Potassium Phosphate bulk with DMF, CEP offered by Merck KGaA

    Find a price of Praziquantel bulk with DMF, CEP offered by Merck KGaA

    Find a price of Urea API bulk with DMF, CEP offered by Merck KGaA

    Find a price of Calcium Chloride bulk with DMF offered by Merck KGaA

    Find a price of Calcium Chloride Monohydrate bulk with JDMF offered by Merck KGaA

    Find a price of Safinamide Methanesulfonate bulk with JDMF offered by Merck KGaA

    Find a price of Sodium Acetate Trihydrate bulk with DMF offered by Merck KGaA

    Find a price of Sodium Fluoride bulk with CEP offered by Merck KGaA

    Find a price of Trisodium Citrate Dihydrate bulk with DMF offered by Merck KGaA

    Find a price of Zinc Dichloride bulk with CEP offered by Merck KGaA

    Find a price of Culture medium/culture medium additives: Cellvento Feed-220 HTST-ready bulk with JDMF offered by Merck KGaA

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search